
Insights on FDA device regulation and the effect on the MedTech community
| Platform | Pricing | Only free issues | Publishes | Weekly | |
|---|---|---|---|---|---|
| Issues | 29 | Subscribers | Read | steveilverman.substack.com |
Curious about how many subscribers What the FDA? has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Recent posts by this newsletter. Browse the email archive.
CDRH just released its guidance priority list for fiscal year 2026 (FY26), saying it will finalize guidance on real-world evidence (RWE) and predetermined change control plans (PCCPs). But what does this list actually tell us about what CDR...
Trump’s drug reshoring push is an alarm bell for device firms. While Trump didn’t target devices, his America First stance means that device companies must be ready for similar treatment. Smart firms will get ahead of the reshoring push bef...
FDA is ramping up warning letters. As its recent drug-advertising blitz shows, FDA is ready to act, publicly and aggressively, to send enforcement messages. And the push goes beyond drug makers; there’s been a spike in device warning letter...
Today's column is a lightly edited version of an article I co-wrote with the awesome Eric Henry, focused on the Quality Management System Regulation (QMSR). The article highlights parts of the QMSR that MedTech firms should pay attention to...
Other publications recommended by the authors of this newsletter.
The writers behind this newsletter.
Steve Silverman is the President of The Silverman Group, a consultancy that serves medical product companies on regulatory, strategy, and policy issues. Steve’s experience includes extensive time in senior FDA roles.
You can find recent issues that have been published by What the FDA? on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to What the FDA?, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch What the FDA? as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact What the FDA? using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Similar Newsletters to see other publications like What the FDA?. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.